Literature DB >> 10541388

The CT appearance of pleural and extrapleural disease in lymphoma.

S L Aquino1, M Y Chen, W T Kuo, C Chiles.   

Abstract

OBJECTIVE: Pleural effusions in patients with lymphoma that are assumed to be related to malignancy are attributed to either lymphatic obstruction by tumour with resultant decreased clearance of pleural fluid, or direct tumour involvement of the pleura. The purpose of our study was to determine how often pleural or extrapleural disease was detected by computed tomography (CT) of patients with pleural effusions and primary or recurrent lymphoma. METHODS AND MATERIALS: We reviewed CT examinations showing evidence of pleural effusion in 61 patients with a diagnosis of primary or recurrent lymphoma and no history of other systemic disorders, including infection. The study population consisted of patients with non-Hodgkin's lymphoma (n = 44) or Hodgkin's disease (n = 17); both primary disease (n = 11) and recurrent disease (n = 50) were represented. Each CT examination was evaluated for the presence of disease involving the visceral and parietal pleura and extrapleural space, mediastinal adenopathy, and pulmonary parenchymal disease.
RESULTS: Fourteen patients (23%) (nine with non-Hodgkin's lymphoma and five with Hodgkin's disease) had parietal pleural disease (thickening or nodules). Eighteen patients (30%) (14 with non-Hodgkin's lymphoma, four with Hodgkin's disease) had tumour or enlarged lymph nodes in the extrapleural space. Forty-three patients (70%) had mediastinal lymphadenopathy. Patients who received intravenous contrast did not have evidence of visceral pleural abnormalities or underlying pulmonary parenchymal disease.
CONCLUSION: Forty-one percent of the patients with lymphoma and pleural effusions had CT evidence of pleural and/or extrapleural disease. The majority of the patients with extrapleural disease had adjacent posterior mediastinal disease.

Entities:  

Mesh:

Year:  1999        PMID: 10541388     DOI: 10.1016/s0009-9260(99)91084-x

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  8 in total

1.  Primary pleural lymphoma: plaque-like thickening of the pleura.

Authors:  Anastasia Oikonomou; Alexandra Giatromanolaki; Dimitrios Margaritis; Marios Froudarakis; Panos Prassopoulos
Journal:  Jpn J Radiol       Date:  2010-01-30       Impact factor: 2.374

2.  The pleural sandwich sign in two cases of primary pleural lymphoma.

Authors:  Yookyung Kim; Myungjae Lee; Yon Ju Ryu; Min-Sun Cho
Journal:  Korean J Radiol       Date:  2015-01-09       Impact factor: 3.500

Review 3.  Diffuse neoplasms of the pleural serosa.

Authors:  L Cardinale; F Ardissone; F Asteggiano; E M Laugelli; D Penna; C Fava
Journal:  Radiol Med       Date:  2012-09-17       Impact factor: 3.469

4.  Diagnostic value of medical thoracoscopy in malignant pleural effusion induced by non-Hodgkin's lymphoma.

Authors:  Zhen Wang; Yan-Bing Wu; Li-Li Xu; Mu-Lan Jin; Xiao-Li Diao; Xiao-Juan Wang; Zhao-Hui Tong; Huan-Zhong Shi
Journal:  Oncol Lett       Date:  2017-10-19       Impact factor: 2.967

Review 5.  Surgical and other invasive approaches to recurrent pleural effusion with malignant etiology.

Authors:  Siyamek Neragi-Miandoab
Journal:  Support Care Cancer       Date:  2008-02-08       Impact factor: 3.603

6.  A Case of Periaortic Lymphoma Mimicking Complicated Type B Acute Aortic Dissection: A Pitfall in the Endovascular Surgery Era.

Authors:  Yuki Imamura; Norihiro Kondo; Yoshiaki Saito; Kaoru Ogawa; Mari Chiyoya; Ikuo Fukuda
Journal:  Ann Vasc Dis       Date:  2020-09-25

7.  Characteristics of pleural effusion with a high adenosine deaminase level: a case-control study.

Authors:  Masafumi Shimoda; Aya Hirata; Yoshiaki Tanaka; Kozo Morimoto; Takashi Yoshiyama; Kozo Yoshimori; Takeshi Saraya; Haruyuki Ishii; Ken Ohta
Journal:  BMC Pulm Med       Date:  2022-09-21       Impact factor: 3.320

8.  Rare case of primary pleural lymphoma presenting with pleural effusion.

Authors:  Mei-Ling Sun; Bin Shang; Jian-Hua Gao; Shu-Juan Jiang
Journal:  Thorac Cancer       Date:  2015-03-26       Impact factor: 3.500

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.